(+035) 527-1710-70
- NEWS AND VIEWS
Comprehending how diet plan impacts tumour development might cause much better treatments. Analysis in mice exposes that a low-calorie diet plan, however not a ketogenic diet plan, slows the development of pancreatic cancer. This result is moderated by lipid modifications.
-
Giulia Salvadori
-
Giulia Salvadori is at the IFOM, FIRC Institute of Molecular Oncology, Milan 20139, Italy, and in the Department of Oncology and Hemato-oncology, University of Milan.
-
-
Valter D. Longo
-
Valter D. Longo is at the IFOM, FIRC Institute of Molecular Oncology, Milan 20139, Italy, and in the Longevity Institute and Davis School of Gerontology, University of Southern California, Los Angeles, California, USA.
-
Various diet plans, such as those that regularly limit calorie consumption and thus drive metabolic modifications related to fasting (regular fasting-mimicking diet plans) 1, or ones that are low in carbs and high in fat (ketogenic diet plans), are becoming dietary interventions that can postpone cancer development and possibly improve the result of anticancer drugs 1, 2 Whereas long-lasting calorie limitation is not practical for individuals on the majority of cancer treatments since it results in weight-loss and lean body mass 3, ketogenic diet plans and routine fasting-mimicking diet plans are starting to be checked in a series of medical trials, and are especially appealing when utilized in mix with basic treatments 1, 2, 4— 6 Composing in Nature, Lien et al 7 fill in a few of the missing out on information about how diet plan impacts cancer development.
Access choices
Subscribe to Journal
Get complete journal gain access to for 1 year
₤19900
just ₤ 3.90 per concern
Tax computation will be settled throughout checkout.
Rent or Buy short article
Get time restricted or complete short article gain access to on ReadCube.
from$ 8.99
All costs are NET costs.
doi: https://doi.org/101038/ d41586-021-02775 -1
References
- 1.
de Groot, S. et al. Nature Commun.11, 3083 (2020).
PubMed.
Post.Google Scholar.
- 2.
Zahra, A. et al. Radiat. Res.187, 743–754(2017).
PubMed.
Post.Google Scholar.
- 3.
Dirks, A. J. & Leeuwenburgh, C. Mech Ageing Dev.127, 1– 7 (2006).
PubMed.
Short article.Google Scholar.
- 4.
Nencioni, A., Caffa, I., Cortellino, S. & Longo, V. D. Nature Rev. Cancer18, 707–719(2018).
PubMed.
Post.Google Scholar.
- 5.
Hopkins, B. D. et al. Nature560, 499–503(2018).
PubMed.
Short article.Google Scholar.
- 6.
Douris, N. et al. Biochim. Biophys. Acta1852, 2056–2065(2015).
PubMed.
Post.Google Scholar.
- 7.
Lien, E. C. et al. Nature https://doi.org/101038/ s41586-021-04049 -2 (2021).
Article.
Google Scholar.
- 8.
Hay N. Nature Rev. Cancer16, 635–649(2016).
PubMed.
Post.Google Scholar.
- 9.
Lee, C. et al. Sci. Transl. Medication. 4, 124 ra27(2012).
PubMed.
Post.Google Scholar.
- 10
Caffa, I. et al. Nature583, 620–624(2020).
PubMed.
Short article.Google Scholar.
- 11
Di Tano, M. et al. Nature Commun.11, 2332 (2020).
PubMed.
Post.Google Scholar.
- 12
D’Aronzo, M. et al. Oncotarget 6, 18545–18457(2015).
PubMed.
Short article.Google Scholar.
Download recommendations
Competing Interests
V.D.L. has equity interest in L-Nutra, a business that produces medical food. He does not get speaking with costs from L-Nutra and has actually dedicated 100%of his shares to charity.
